Previous 10 | Next 10 |
How Do Penny Stock Traders Follow The Money? One of the most exciting things about trading penny stocks is making quick money. But finding companies to add to your watch list can be easier said than done. There are plenty of trading strategies to use to do so, and one of the more po...
NGM Biopharmaceuticals ( NASDAQ: NGM ) on Monday said its phase 2 trial of its monoclonal antibody NGM621 for the treatment of eye disease geographic atrophy failed to meet its main goal. Shares of the small-cap biotech plunged 72.2% to $3.21 in premarket trading. ...
Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham NGM621 showed favorable safety and tolerability, with no evidence of increased CNV conversion and no treatment-related SAEs ...
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety results from its CATALINA Phase ...
Summary Today we take our first look at Apellis Pharmaceuticals, a midcap concern with an advancing pipeline. Its flagship product was rolled out last year, is pursuing other indications, and could eventually achieve blockbuster status. However, some insiders are selling and q...
NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer NGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 + gemcitabine + Nab-paclitaxel) with no dose-limiting toxicities ...
NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer NGM120 has been well tolerated to date in patients in the Phase 1a study with no dose-limiting toxicities Two of five prostate cancer patients in the Phase 1...
Poster presentation at upcoming ESMO Annual Congress to highlight analysis of subgroup of patients with prostate cancer in NGM120 Phase 1a trial Short-talk presentation at upcoming AACR Special Conference: Pancreatic Cancer to highlight analysis of patients with advanced pancreatic ca...
NGM Biopharmaceuticals press release ( NASDAQ: NGM ): Q2 GAAP EPS of -$0.59 misses by $0.04 . Revenue of $8.29M (-50.6% Y/Y) misses by $5.11M . For further details see: NGM Biopharmaceuticals GAAP EPS of -$0.59 misses by $0.04, revenue of $8.29M misses by...
--Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA ® (pembrolizumab) for the treatment of patients with advanced solid tumors-- --Initiated the Phase1b portion of the Phase 1/2 tria...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...